GlassScriptPhysician profile
Michael F Donovan
NPI 1669852448
$77,914.71
in general payments reported to CMS, 2019-2025
52 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.45 · 2021: $1,058 · 2022: $3,373 · 2023: $3,688 · 2024: $43K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Food and Beverage: $13K · Travel and Lodging: $8,748 · Consulting Fee: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,050.00 |
| Food and Beverage | $12,920.06 |
| Travel and Lodging | $8,747.79 |
| Consulting Fee | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $62,962.78 | 2021-2025 | Apretude, Dovato, Cabenuva |
| Gilead Sciences, INC. | $5,078.87 | 2021-2025 | Biktarvy, Yeztugo, Descovy |
| Napo Pharmaceuticals INC | $866.41 | 2021-2025 | Mytesi |
| Merck Sharp & Dohme LLC | $808.19 | 2021-2025 | Pifeltro, Delstrigo, Gardasil 9 |
| Pfizer INC. | $700.00 | 2021-2025 | |
| Abbvie INC. | $679.11 | 2021-2025 | Mavyret, Qulipta, Vraylar |
| Novo Nordisk INC | $673.06 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Emd Serono, INC. | $553.08 | 2021-2025 | Serostim |
| Theratechnologies INC. | $500.42 | 2022-2025 | Trogarzo, Egrifta |
| Lilly USA, LLC | $452.92 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $389.26 | 2021-2025 | Repatha, Otezla, Repatha |
| Antares Pharma, INC. | $351.35 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Astrazeneca Pharmaceuticals LP | $345.78 | 2020-2024 | Farxiga, Breztri, Evusheld |
| Abbott Laboratories | $307.17 | 2022-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $284.21 | 2022-2025 | Spravato, Xarelto |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Donovan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.